Metso completes the acquisition of the construction

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Metso completes the acquisition of the construction equipment supplier Shaorui Heavy Industries Ltd. in China

HELSINKI, Finland, Sept. 27, 2013 (GLOBE NEWSWIRE) --

Metso Corporation's press release on September 27, 2013 at 11:00 a.m. local time Metso continues to strengthen its presence in the fast growing Chinese construction market through the completion of the acquisition of Shaorui Heavy Industries Ltd. (Shaorui), announced in November 2012. Located in Shaoguan in Guangdong Province, Shaorui is one of the leading mid-market crushing and screening equipment producers in China. 75 percent ownership of Shaorui and approximately 330 employees will transfer to Metso as of today. Metso has an option to purchase the remaining 25 percent of the company in the future. The value of the acquisition will not be disclosed. "The acquisition is an important step for us and helps us gain deeper knowledge of the products and customers in the Chinese construction  markets. Our aim is to better serve the needs of our Chinese customers by developing a market driven technology offering for China. This will be done by utilizing the technological know-how of both Shaorui and Metso to further enhance our product offering", states Pekka Pohjoismäki, President, Crushing and Screening business line, Mining and Construction, Metso. Furthermore, it forms a good platform for future growth in terms of the leading crushing and screening market position by combining Metso's current premium product offering with Shaorui's excellence in mid-market products. After the acquisition, Metso will have a better product portfolio for penetrating also to other emerging markets. "Our recent actions in China, the acquisition of Shaorui Heavy Industries Ltd. and the joint venture with LiuGong Group Corp. Ltd., announced last November, significantly strengthen our supply capabilities for the Chinese construction industry", he continues. Metso in China The year 2013 marks Metso's 80-year anniversary in China. The company's first contract from China, a paper machine delivery, was signed in 1933. Today, Metso has a strong and well-established presence in China. Metso's about 3,500 employees in China address local customer needs in all Metso's key customer industries, and support the sustainable development of China's industries and infrastructure. Shaorui Heavy Industries Ltd. is one of the leading mid-market crushing and screening equipment producers in China. It employs some 330 people. Shaorui has a leading local market position and a well-known brand in South China; it is headquartered in Shaoguan of Guangdong Province. Metso's mining and construction professionals specialize in always bringing the right technology, processes, machinery and services to our customers in aggregates production, construction, mining and minerals processing. www.metso.com/miningandconstruction Metso is a global supplier of technology and services to customers in the process industries, including mining, construction, pulp and paper, power, and oil and gas. Our 30,000 professionals based in over 50 countries contribute to sustainability and deliver profitability to customers worldwide. Metso's shares are listed on the NASDAQ OMX Helsinki Ltd. www.metso.com , www.twitter.com/metsogroup For further information, please contact: Pekka Pohjoismäki, President, Crushing and Screening Equipment business line, Mining and Construction, Metso, tel. +358 400 334 400 Xiaofeng Liang, SVP China market area, Mining and Construction, Metso, tel. +86 138 012 889 53 [HUG#1731916]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 11

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 7

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 7

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 11

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 4

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 10

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 6

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 10

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 5

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

Chart Industries Transitions to New Leadership in Upcoming Merger

Updated Category News Views 231

Chart Industries Announces Leadership Change Chart Industries (NYSE: GTLS) is taking significant steps toward a future transition as CEO Jill Evanko has announced plans to assume a senior advisor role starting in early 2026. This change comes as she prepares to take on a new executive opportunity within a privately owned company. Evanko has been essential in steering the...

Continue Reading
Understanding Debtors: Insights into Realkredit Danmark A/S

Updated Category News Views 299

Understanding Debtors: Key Insights from Realkredit Danmark A/S At the heart of any effective financial institution is a reliable understanding of its debtors. Realkredit Danmark A/S, a prestigious name in the financial landscape, recently made available a detailed breakdown of its debtors. This information is crucial for various stakeholders, including investors,...

Continue Reading
Cryptocurrency Market Update: Bitcoin Droops under $59K with ETF Inflows Soaring

Updated Category News Views 148

Bitcoin's Recent Performance The cryptocurrency market has been lively lately, especially with Bitcoin recently falling below the $59,000 threshold. Investors had been optimistic, especially since the cryptocurrency saw a remarkable $436 million in net ETF inflows just last week. This significant influx signals that institutional interest in cryptocurrencies is still...

Continue Reading
Enhancing Specialized Care for ARFID Treatment with Emily Program

Updated Category News Views 169

Introduction to The Emily Program and ARFID The Emily Program is making significant strides in specialized care for individuals with Avoidant/Restrictive Food Intake Disorder (ARFID). This condition, often misunderstood, has recently begun to garner more attention from healthcare experts. In response to this need, The Emily Program is offering advanced treatment...

Continue Reading
Investigation of Alleged Securities Fraud at 3D Systems Unfolds

Updated Category News Views 167

Overview of Legal Actions Against 3D Systems Corporation Recently, investors in 3D Systems Corporation have found themselves entangled in a potential securities fraud lawsuit. This case serves as a cautionary tale, highlighting the importance of transparency and integrity in corporate communication. The allegations stem from assertions that the company made misleading...

Continue Reading